Australia - engleză - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - esomeprazole magnesium trihydrate, quantity: 22.3 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: microcrystalline cellulose; crospovidone; purified talc; iron oxide yellow; sodium stearylfumarate; synthetic paraffin; methacrylic acid copolymer; hypromellose; hyprolose; triethyl citrate; iron oxide red; magnesium stearate; polysorbate 80; glyceryl monostearate; titanium dioxide; macrogol 6000; maize starch; sucrose - healing of duodenal ulcer associated with helicobacter pylori and eradication of helicobacter pylori in patients with active or healed peptic ulcer.

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

rebel distributors corp - esomeprazole magnesium (unii: r6dxu4way9) (esomeprazole - unii:n3pa6559ft) - esomeprazole 20 mg - healing of erosive esophagitis nexium is indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. for those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of nexium may be considered. maintenance of healing of erosive esophagitis nexium is indicated to maintain symptom resolution and healing of erosive esophagitis. controlled studies do not extend beyond 6 months. symptomatic gastroesophageal reflux disease nexium is indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with gerd in adults and children 1 year or older. nexium is indicated for the reduction in the occurrence of gastric ulcers associated with continuous nsaid therapy in patients at risk for developing gastric ulcers. patients are considered to be at risk due to their age (≥ 60) and/or documented history of gastric ulcers. controlled studies do not extend beyond 6 months. t

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

stat rx usa llc - esomeprazole magnesium (unii: r6dxu4way9) (esomeprazole - unii:n3pa6559ft) - esomeprazole magnesium 20 mg - healing of erosive esophagitis nexium is indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. for those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of nexium may be considered. maintenance of healing of erosive esophagitis nexium is indicated to maintain symptom resolution and healing of erosive esophagitis. controlled studies do not extend beyond 6 months. symptomatic gastroesophageal reflux disease nexium is indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with gerd in adults and children 1 year or older. nexium is indicated for the reduction in the occurrence of gastric ulcers associated with continuous nsaid therapy in patients at risk for developing gastric ulcers. patients are considered to be at risk due to their age (≥ 60) and/or documented history of gastric ulcers. controlled studies do not extend beyond 6 months. t

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

physicians total care, inc. - esomeprazole magnesium (unii: r6dxu4way9) (esomeprazole - unii:n3pa6559ft) - esomeprazole 20 mg - healing of erosive esophagitis nexium is indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. for those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of nexium may be considered. in infants 1 month to less than 1 year, nexium is indicated for short-term treatment (up to 6 weeks) of erosive esophagitis due to acid-mediated gerd. maintenance of healing of erosive esophagitis nexium is indicated to maintain symptom resolution and healing of erosive esophagitis. controlled studies do not extend beyond 6 months. symptomatic gastroesophageal reflux disease nexium is indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with gerd in adults and children 1 year or older. nexium is indicated for the reduction in the occurrence of gastric ulcers associated with continuous nsaid therapy in patients at risk for developing gastric ulcers. patient

Australia - engleză - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - esomeprazole magnesium trihydrate -

Australia - engleză - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - clarithromycin; amoxycillin; esomeprazole magnesium trihydrate -

Australia - engleză - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - esomeprazole sodium -

Australia - engleză - Department of Health (Therapeutic Goods Administration)

haleon australia pty ltd - esomeprazole magnesium trihydrate, quantity: 22.3 mg (equivalent: esomeprazole, qty 20 mg) - capsule, hard - excipient ingredients: hypromellose; propylene glycol; indigo carmine aluminium lake; carmine; magnesium stearate; gelatin; purified talc; methacrylic acid copolymer; titanium dioxide; erythrosine; iron oxide yellow; indigo carmine; povidone; shellac; triethyl citrate; sodium hydroxide; allura red ac; glyceryl monostearate; polysorbate 80; hyprolose; sucrose; hydrolysed maize starch - nexium 24hr once daily dosing is indicated for the symptomatic relief of frequent heartburn, acid regurgitation and other symptoms associated with gastro-oesophageal reflux disease (gord).

Israel - engleză - Ministry of Health

taro international ltd, israel - esomeprazole as sodium - powder for solution for inj/inf - esomeprazole as sodium 40 mg/dose - esomeprazole - esomeprazole - nexium for iniection and infusion is indicated in adult for:• gastroesophageal reflux disease (gerd) in patients with esophagitis and/or severe symptoms of reflux as an alternative to oral therapy when oral intake is not appropriate. • prevention of rebleeding following therapeutic endoscopy for acute bleeding gastric or duodenal ulcers.nexium for injection and infusion is indicated in children and adolescents aged 1-18 years for:• gastric antisecretory treatment when the oral route is not possible, such as:gastroesophageal reflux disease (gerd) in patients with erosive reflux esophagitis and/or severe symptoms of reflux.

Malta - engleză - Malta Medicines Authority

astrazeneca ab se-151 85, södertälje, sweden - esomeprazole - gastro-resistant granules granules for oral suspension - esomeprazole 10 mg - drugs for acid related disorders